Przemek Obloj

Chief Financial Officer

2024

bit.bio is a synthetic biology company focused on human cells that is advancing medicine (UN SDG9) and enabling curative treatments (UN SDG3). The company does this by industrialising the manufacture of human cells and making them more accessible. bit.bio was spun out of the University of Cambridge in 2016 and has since raised approximately $200m from investors such as Arch Venture, Foresite Capital, Milky Way, Charles River Laboratories, National Resilience, Tencent, Verition Fund and Puhua Capital. bit.bio’s opti-ox™ precision cell programming and manufacturing technology enables conversion of induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step. This can be achieved within days and at industrial scale, while maintaining exceptional purity and unparalleled consistency.

Investor

2021

Investment Advisory Board Member

2020

Managing Partner & CIO

2020 - 2023

Managing Director, Head of European Private Equity

2016 - 2020

Private Equity and Growth investing across Europe and the U.S.

Director

2009 - 2016

Investor

2007 - 2009

Analyst / Associate / Manager, Private Equity & Corporate Finance Practice

2000 - 2007

Analyst / Data Scientist

1998 - 2000

Provided data and analytical support to the Minister of Labour implementing a comprehensive pension reform in Poland, including a switch to a defined contribution scheme and introduction of funded element (pension funds)